Lymphangioleiomyomatosis

Background

  • Lymphangioleiomyomatosis (LAM) is a rare, progressive, low-grade neoplastic lung disease characterized by infiltration of abnormal smooth muscle-like cells (LAM cells) into the lung parenchyma, lymphatics, and blood vessels, resulting in diffuse thin-walled cystic destruction of both lungs.[1] It almost exclusively affects women of childbearing age (mean diagnosis ~35 years).
  • LAM cells harbor mutations in tuberous sclerosis complex (TSC) genes causing constitutive activation of the mTOR pathway.[2] ED physicians will most commonly encounter LAM patients presenting with recurrent spontaneous pneumothorax, chylous pleural effusion, or progressive dyspnea — and the diagnosis may not yet be established.
  • LAM occurs in two forms:[1]
    • Sporadic LAM (S-LAM): Somatic TSC2 mutations; ~3.4–7.8 per million women; no family inheritance
    • TSC-associated LAM (TSC-LAM): 30–40% of women with tuberous sclerosis develop LAM; autosomal dominant TSC1 or TSC2 germline mutations
  • LAM cells are neoplastic smooth muscle-like cells that express smooth muscle actin, HMB-45 (melanocytic marker — key for pathologic diagnosis), and estrogen/progesterone receptors[3]
  • Estrogen dependence: LAM almost exclusively affects premenopausal women; may accelerate during pregnancy and with exogenous estrogen; decelerates after menopause[1]
  • Pathogenesis: TSC gene mutations → loss of hamartin/tuberin tumor suppressor complex → constitutive mTORC1 activation → uncontrolled cell proliferation, lymphangiogenesis, and cystic lung destruction[2]
  • LAM cells metastasize via the lymphatics (LAM is considered a low-grade metastasizing neoplasm with likely uterine origin)[2]
  • Proliferation of LAM cells obstructs bronchioles (→ air trapping, bullae, pneumothorax), lymphatics (→ chylous effusions), and venules (→ hemoptysis)[4]
  • Extrapulmonary manifestations:
    • Renal angiomyolipomas (AML): Present in ~30–40% of S-LAM and ~80% of TSC-LAM; benign fat-containing tumors; may hemorrhage (especially >4 cm)[3]
    • Lymphangioleiomyomas: Cystic masses of the axial lymphatics; abdominopelvic lymphadenopathy
    • Chylous effusions: Chylothorax (~20%) and/or chylous ascites from lymphatic obstruction[5]
    • Increased frequency of meningiomas[3]
  • Epidemiology: ~3.4–7.8 per million women (sporadic LAM); prevalence likely underestimated due to delayed diagnosis (average 5–6 years from symptom onset)[1]
  • FEV1 declines at ~75–118 mL/year in untreated patients[6]
  • >90% 10-year survival with modern management[7]

Clinical Features

  • Progressive exertional dyspnea — the most common symptom; insidious onset; often attributed to asthma or deconditioning for years before diagnosis[1]
  • Recurrent spontaneous pneumothorax:[2]
    • Occurs in ~66% of LAM patients during their lifetime
    • Presenting manifestation in ~25% of patients — this is often how LAM is first diagnosed
    • Recurrence rate >70% if managed conservatively (observation/aspiration alone)
    • Lifetime average of 3–4 pneumothoraces per patient
    • May be bilateral or alternating sides
  • Chylous pleural effusion (chylothorax): ~20% of patients; milky fluid; elevated triglycerides (>110 mg/dL)[5]
  • Hemoptysis: Usually mild; from venule obstruction by LAM cells
  • Cough (often nonproductive)
  • Fatigue
  • Wheezing: ~20–25% of LAM patients have a reversible obstructive (asthma-like) component responsive to bronchodilators[5]
  • Physical exam is often unremarkable early in disease
    • Advanced disease: decreased breath sounds, scattered wheezes, hyperresonance
    • Absent breath sounds unilaterally → pneumothorax or large effusion
    • Abdominal mass → lymphangioleiomyoma or hemorrhaging AML
    • Signs of tuberous sclerosis: facial angiofibromas, ungual fibromas, shagreen patches, hypomelanotic macules, cortical tubers
  • ED red flags suggesting LAM in a previously undiagnosed patient:
    • Young woman with recurrent spontaneous pneumothorax (especially bilateral or alternating)
    • Spontaneous pneumothorax in a woman with known tuberous sclerosis
    • Chylous (milky) pleural effusion in a young woman
    • Diffuse bilateral cysts found incidentally on chest CT performed for other reasons
    • Retroperitoneal hemorrhage from ruptured renal AML

Differential Diagnosis

Diffuse cystic lung diseases (the primary radiologic differential):[2]

  • Pulmonary Langerhans cell histiocytosis (cysts + nodules; spares costophrenic angles; smoker; irregularly shaped cysts)
  • Lymphocytic interstitial pneumonia (LIP — cysts with ground-glass opacities; associated with Sjögren syndrome and HIV)
  • Birt-Hogg-Dubé syndrome (autosomal dominant; cysts predominantly basilar and medial; renal tumors are chromophobe or oncocytoma, not AML; skin fibrofolliculomas)
  • Emphysema (COPD) — older, smoker; centrilobular distribution; no true thin walls
  • Amyloidosis (rare cystic form)
  • Light-chain deposition disease

Other causes of recurrent pneumothorax in young women:

Other:

Acute dyspnea

Emergent

Non-Emergent


Pulmonary Fibrosis

Acute dyspnea

Emergent

Non-Emergent

Evaluation

Workup

Laboratory (ED):

  • CBC, basic metabolic panel, lactate
  • ABG/VBG: hypoxemia in advanced disease or acute pneumothorax
  • Pleural fluid analysis if thoracentesis performed: chylous effusion — milky/turbid; triglycerides >110 mg/dL is diagnostic of chylothorax; cholesterol/triglyceride ratio <1 distinguishes chyle from pseudochylothorax; lymphocyte-predominant[1]
  • Serum VEGF-D (vascular endothelial growth factor-D): Not an ED test, but understand its role — ≥800 pg/mL is 100% specific for LAM in the setting of compatible cystic lung disease on CT; eliminates need for biopsy in most cases; low levels (<800 pg/mL) do not exclude LAM (high false-negative rate)[1]
  • If renal AML suspected (flank pain, hematuria, retroperitoneal hemorrhage): hemoglobin/hematocrit, type and screen, renal function, urinalysis

Imaging:

Chest X-ray:

  • May be normal early in disease
  • Increased lung volumes (hyperinflation) — unlike most ILDs which cause volume loss
  • Reticulonodular pattern
  • Pneumothorax
  • Pleural effusion
  • Preserved or increased lung volumes despite diffuse interstitial changes is a key clue (most ILDs cause volume loss; LAM causes hyperinflation from air trapping)

HRCT — the key diagnostic imaging study:

  • Diffuse, bilateral, round or ovoid, thin-walled cysts distributed uniformly throughout both lungs — the hallmark finding[1]
  • Cysts are typically 2–5 mm but can range from 1 mm to 30 mm
  • No zonal predominance (cysts affect upper, middle, and lower zones equally) — distinguishes from Langerhans cell histiocytosis (upper-zone predominant, spares bases) and Birt-Hogg-Dubé (basilar/medial)
  • Intervening lung parenchyma appears normal (no ground-glass opacities, nodules, or consolidation)
  • Ground-glass opacities suggest alternative or superimposed diagnosis
  • May also show: pneumothorax, pleural effusion, mediastinal/hilar lymphadenopathy, pericardial effusion
  • HRCT alone is NOT sufficient for definitive diagnosis per ATS/JRS 2017 guidelines — requires additional confirmatory features (see Diagnosis below)[8]

CT abdomen/pelvis (coordinate with inpatient/outpatient team):

  • Renal angiomyolipomas: fat-containing renal masses (classically fat-density on CT); may be bilateral and multiple; risk of hemorrhage if >4 cm
  • Retroperitoneal lymphangioleiomyomas
  • Lymphadenopathy
  • Chylous ascites

Pulmonary function tests (outpatient — understand the pattern):

  • Obstructive or mixed obstructive-restrictive pattern (unlike most ILDs which are purely restrictive)[1]
  • Reduced FEV1, reduced FEV1/FVC ratio
  • Reduced DLCO (often the earliest abnormality)
  • Increased residual volume (air trapping)
  • ~20–25% have bronchodilator responsiveness[5]

Diagnosis

  • Definitive diagnosis of LAM can be made without biopsy when characteristic cystic lung disease on HRCT is present plus any ONE of the following:[1]
    • (1) Diagnosis of tuberous sclerosis
    • (2) Serum VEGF-D ≥800 pg/mL
    • (3) Renal angiomyolipoma (confirmed by imaging)
    • (4) Lymphangioleiomyoma
    • (5) Chylous effusion (pleural or ascitic)
  • HRCT findings alone are insufficient for definitive diagnosis (per ATS/JRS 2017) due to overlap with other cystic lung diseases; requires confirmatory clinical, radiologic, or serologic feature[8]
  • If no confirmatory features: consider transbronchial lung biopsy (HMB-45 staining is highly specific) or surgical lung biopsy[8]
  • In the ED: The goal is not to definitively diagnose LAM, but to recognize the pattern (young woman + recurrent pneumothorax + diffuse cysts on CT) and ensure appropriate referral

Management

ED management is primarily supportive and complication-directed:

1. Pneumothorax management:

  • Treat per standard pneumothorax protocols: observation for small pneumothorax without respiratory distress; chest tube thoracostomy (pigtail or surgical) for symptomatic or large pneumothorax[5]
  • Critical LAM-specific point: Recurrence rate is >70% with conservative management alone; ATS/JRS guidelines recommend pleurodesis after the FIRST pneumothorax rather than waiting for recurrence[8]
  • VATS-guided mechanical abrasion is the preferred initial pleurodesis modality; chemical pleurodesis (talc) is reserved for recurrence after initial pleurodesis[5]
  • Prior pleurodesis is NOT a contraindication for future lung transplantation (ATS/JRS 2017) — this is critical to know, as outdated teaching suggested otherwise and may cause clinicians to delay pleurodesis[8]
  • Consult thoracic surgery early for patients with known or suspected LAM and pneumothorax
  • Sirolimus note: sirolimus impairs wound healing and may need to be withheld during active air leak management — discuss with the patient's pulmonologist[5]

2. Chylous effusion:

  • Thoracentesis for symptomatic chylothorax — send fluid for triglycerides, cell count, LDH, protein, cultures
  • Chylous effusions respond well to sirolimus (first-line medical treatment rather than invasive procedures)[5]
  • Avoid repeated thoracentesis when possible (nutritional depletion from chyle loss; consider dietary modification with medium-chain triglycerides)
  • Pleurodesis or thoracic duct ligation for refractory cases

3. Renal AML hemorrhage:

  • Acute retroperitoneal hemorrhage from ruptured AML: hemodynamic resuscitation, emergent CT angiography, selective arterial embolization is preferred over nephrectomy (nephron-sparing approach)[3]
  • AML >4 cm: higher hemorrhage risk; elective embolization or mTOR inhibitor therapy to shrink tumor

4. Respiratory support:

  • Supplemental O2 to maintain SpO2 ≥90%[5]
  • Bronchodilators (albuterol) — may benefit the ~20–25% with reversible airway obstruction; reasonable to trial in any symptomatic LAM patient[5]
  • Non-invasive ventilation or intubation for respiratory failure

5. Disease-modifying therapy (outpatient — coordinate with pulmonology):

  • Sirolimus (rapamycin) — the only FDA-approved treatment for LAM; mTORC1 inhibitor[6]
    • MILES trial: stabilized FEV1 decline (placebo lost 12 mL/month vs. sirolimus gained 1 mL/month; p<0.001); reduced serum VEGF-D; improved quality of life[6]
    • Treatment is suppressive, not curative — long-term continuous therapy required; disease progresses again upon discontinuation[5]
    • Sirolimus also reduces pneumothorax recurrence by ~80% and is first-line for chylous effusions and AML[9]
    • Indications: FEV1 <70% predicted, FEV1 decline ≥90 mL/year, refractory chylous effusions, AML ≥4 cm, significant disease burden[5]
    • Side effects: oral mucositis (most common), hyperlipidemia, diarrhea, peripheral edema, delayed wound healing, increased infection risk, ovarian cysts
  • Everolimus: Alternative mTOR inhibitor; FDA-approved for TSC-associated AML and subependymal giant cell astrocytoma; similar efficacy and side effect profile
  • Avoid estrogen-containing medications: oral contraceptive pills, hormone replacement therapy — may accelerate disease[1]
  • Lung transplantation for end-stage disease (FEV1 <30% predicted or severe functional limitation); note: LAM can recur in transplanted lung[1]

Disposition

  • Admit:
    • Pneumothorax requiring chest tube (strongly consider thoracic surgery consultation for pleurodesis discussion given high recurrence rate)
    • Significant chylothorax with respiratory compromise
    • Acute retroperitoneal hemorrhage from renal AML
    • Respiratory failure or new/increased O2 requirement
    • Hemodynamic instability
  • Discharge with close follow-up:
    • Small, stable pneumothorax managed with observation in a patient with adequate oxygenation and close outpatient follow-up assured
    • Known LAM patient with mild exacerbation of dyspnea at baseline, stable vitals, and no evidence of pneumothorax or effusion
    • Suspected new LAM diagnosis (young woman with characteristic CT findings): ensure urgent outpatient pulmonology referral (ideally to a center with LAM expertise)
  • Discharge counseling:
    • Return immediately for sudden chest pain, worsening dyspnea, or hemoptysis (pneumothorax recurrence)
    • Avoid estrogen-containing contraceptives and hormone replacement
    • Air travel: associated with increased pneumothorax risk — discuss with pulmonologist before flying[3]
    • Pregnancy: may accelerate LAM progression; requires pre-pregnancy counseling with a LAM specialist[1]
    • Scuba diving is contraindicated (pneumothorax risk)
    • Do not discontinue sirolimus without discussing with pulmonologist
    • The LAM Foundation (www.thelamfoundation.org) is an excellent patient resource

See Also

External Links

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 Lymphangioleiomyomatosis. StatPearls. NCBI Bookshelf. Updated June 2023.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 McCormack FX, et al. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. Lancet Respir Med. 2021.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 Johnson SR, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010;35(1):14-26.
  4. ↑ Lymphangioleiomyomatosis. Medscape/eMedicine. Updated 2024.
  5. ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 LAM Management. The LAM Foundation. Updated October 2023.
  6. ↑ 6.0 6.1 6.2 McCormack FX, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595-1606.
  7. ↑ Lymphangioleiomyomatosis (LAM). Cleveland Clinic. Updated December 2025.
  8. ↑ 8.0 8.1 8.2 8.3 8.4 Gupta N, et al. Lymphangioleiomyomatosis diagnosis and management: HRCT, transbronchial lung biopsy, and pleural disease management. An official ATS/JRS clinical practice guideline. Am J Respir Crit Care Med. 2017;196(10):1337-1348.
  9. ↑ Cheng C, et al. Sirolimus reduces the risk of pneumothorax recurrence in patients with LAM. Orphanet J Rare Dis. 2022;17(1):257.
Retrieved from "https://www.wikem.org/w/index.php?title=Lymphangioleiomyomatosis&oldid=389176"